681 related articles for article (PubMed ID: 16439711)
21. Therapeutic implications of cholesteryl ester transfer protein inhibitors in hyperlipidemia and low high-density lipoprotein-cholesterolemia.
Inazu A; Mabuchi H
Curr Opin Investig Drugs; 2003 Mar; 4(3):291-7. PubMed ID: 12735230
[TBL] [Abstract][Full Text] [Related]
22. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
Hausenloy DJ; Yellon DM
Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
[TBL] [Abstract][Full Text] [Related]
23. Thyroid hormone increases plasma cholesteryl ester transfer protein activity and plasma high-density lipoprotein removal rate in transgenic mice.
Berti JA; Amaral ME; Boschero AC; Nunes VS; Harada LM; Castilho LN; Oliveira HC
Metabolism; 2001 May; 50(5):530-6. PubMed ID: 11319713
[TBL] [Abstract][Full Text] [Related]
24. Role of lipases, lecithin:cholesterol acyltransferase and cholesteryl ester transfer protein in abnormal high density lipoprotein metabolism in insulin resistance and type 2 diabetes mellitus.
de Vries R; Borggreve SE; Dullaart RP
Clin Lab; 2003; 49(11-12):601-13. PubMed ID: 14651331
[TBL] [Abstract][Full Text] [Related]
25. Increasing high-density lipoprotein cholesterol, inhibition of cholesteryl ester transfer protein, and heart disease risk reduction.
Schaefer EJ; Asztalos BF
Am J Cardiol; 2007 Dec; 100(11 A):n25-31. PubMed ID: 18047849
[TBL] [Abstract][Full Text] [Related]
26. High-density lipoprotein: a fall from grace?
van Leuven SI; Stroes ES; Kastelein JJ
Ann Med; 2008; 40(8):584-93. PubMed ID: 18608128
[TBL] [Abstract][Full Text] [Related]
27. CETP inhibition in cardiovascular risk management: a critical appraisal.
Dullaart RP; Dallinga-Thie GM; Wolffenbuttel BH; van Tol A
Eur J Clin Invest; 2007 Feb; 37(2):90-8. PubMed ID: 17217373
[TBL] [Abstract][Full Text] [Related]
28. Lessons learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial.
Barter P
Am J Cardiol; 2009 Nov; 104(10 Suppl):10E-5E. PubMed ID: 19895939
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease.
Chapman MJ
Pharmacol Ther; 2006 Sep; 111(3):893-908. PubMed ID: 16574234
[TBL] [Abstract][Full Text] [Related]
30. Refocusing on use of cholesteryl ester transfer protein inhibitors.
Kastelein JJ
Am J Cardiol; 2007 Dec; 100(11 A):n47-52. PubMed ID: 18047853
[TBL] [Abstract][Full Text] [Related]
31. [Cholesterol ester transfer protein. A major player in cholesterol metabolism].
Hansen PR
Ugeskr Laeger; 1999 Sep; 161(38):5295-8. PubMed ID: 10536513
[TBL] [Abstract][Full Text] [Related]
32. Important role for bone marrow-derived cholesteryl ester transfer protein in lipoprotein cholesterol redistribution and atherosclerotic lesion development in LDL receptor knockout mice.
Van Eck M; Ye D; Hildebrand RB; Kar Kruijt J; de Haan W; Hoekstra M; Rensen PC; Ehnholm C; Jauhiainen M; Van Berkel TJ
Circ Res; 2007 Mar; 100(5):678-85. PubMed ID: 17293475
[TBL] [Abstract][Full Text] [Related]
33. Dalcetrapib: a review of Phase II data.
Robinson JG
Expert Opin Investig Drugs; 2010 Jun; 19(6):795-805. PubMed ID: 20465364
[TBL] [Abstract][Full Text] [Related]
34. Cholesteryl ester transfer protein inhibition in cardiovascular risk management: ongoing trials will end the confusion.
Kappelle PJ; van Tol A; Wolffenbuttel BH; Dullaart RP
Cardiovasc Ther; 2011 Dec; 29(6):e89-99. PubMed ID: 20645987
[TBL] [Abstract][Full Text] [Related]
35. Anacetrapib: hope for CETP inhibitors?
Gurfinkel R; Joy TR
Cardiovasc Ther; 2011 Oct; 29(5):327-39. PubMed ID: 20406242
[TBL] [Abstract][Full Text] [Related]
36. The cholesteryl ester transfer protein (CETP) TaqIB polymorphism in the cholesterol and recurrent events study: no interaction with the response to pravastatin therapy and no effects on cardiovascular outcome: a prospective analysis of the CETP TaqIB polymorphism on cardiovascular outcome and interaction with cholesterol-lowering therapy.
de Grooth GJ; Zerba KE; Huang SP; Tsuchihashi Z; Kirchgessner T; Belder R; Vishnupad P; Hu B; Klerkx AH; Zwinderman AH; Jukema JW; Sacks FM; Kastelein JJ; Kuivenhoven JA
J Am Coll Cardiol; 2004 Mar; 43(5):854-7. PubMed ID: 14998629
[TBL] [Abstract][Full Text] [Related]
37. Selective CETP inhibition and PPARalpha agonism increase HDL cholesterol and reduce LDL cholesterol in human ApoB100/human CETP transgenic mice.
Hansen MK; McVey MJ; White RF; Legos JJ; Brusq JM; Grillot DA; Issandou M; Barone FC
J Cardiovasc Pharmacol Ther; 2010 Jun; 15(2):196-202. PubMed ID: 20332533
[TBL] [Abstract][Full Text] [Related]
38. Should we take high-density lipoprotein cholesterol levels at face value?
Leite JO; Fernandez ML
Am J Cardiovasc Drugs; 2010; 10(1):1-3. PubMed ID: 20104929
[TBL] [Abstract][Full Text] [Related]
39. [Transfer of plasma cholesterol and atherosclerosis].
Mezdour H; Monte G; Fruchart JC
Ann Biol Clin (Paris); 1994; 52(2):95-102. PubMed ID: 7802346
[TBL] [Abstract][Full Text] [Related]
40. Blockade of scavenger receptor class B type I raises high density lipoprotein cholesterol levels but exacerbates atherosclerotic lesion formation in apolipoprotein E deficient mice.
Kitayama K; Nishizawa T; Abe K; Wakabayashi K; Oda T; Inaba T; Amemiya Y
J Pharm Pharmacol; 2006 Dec; 58(12):1629-38. PubMed ID: 17331327
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
